KVK-Tech recalls Atovaquone Oral Suspension (750 mg/5 mL, 210 mL) due to customer reports of unusual grittiness. This medication is prescription-only and may be affected by specific batch numbers.
“KVK-Tech Atovaquone Oral Suspension Recall: Unusual Grittiness Complaints.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/36101-kvk-tech-atovaquone-oral-suspension-recall-unusual-grittiness-complaints. Based on FDA recall #D-0772-2021 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0772-2021%22&limit=1).
KVK-Tech, Inc. recalled Atovaquone Oral Suspension, USP due to temperature abuse that may cause grittiness, the FDA announced on July 2, 2021. The firm initiated this voluntary Class I recall after receiving customer complaints regarding the product's texture.
The recall addresses temperature abuse of the oral suspension. The firm received customer complaints reporting unusual grittiness in the product.
Context
GovInfoNow's records show KVK Tech, Inc. has had 11 other recalls on record since December 11, 2013. Recent brand recalls include Phentermine Capsules recalled on May 9, 2025, due to manufacturing deviations, and Betaxolol Tablets recalled on September 20, 2023, for the risk of oxycodone contamination. Other recent recalls of similar products include Taro's Children's Ibuprofen recall on March 2, 2026, due to a foreign substance, and Guardian Drug Goodsense Ultra Strength Antacid Tablets recalled on May 28, 2026, for metallic particles.
How to tell if you have this one
Check for the product name 'Atovaquone Oral Suspension, USP, 750 mg/5 mL, 210 mL bottle' with the NDC 10702-223-21. The affected batches are 16653A and 16654A, expiring December 2022.
Brand
KVK-Tech
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Verify the product name, NDC number, and batch numbers to confirm if it is affected.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Product was distributed to one distributor who may have further distributed Nationwide in the USA.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 11 months after the firm started it.
1Firm started the recall
2FDA classified it Class I
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0772-2021 (July 2, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0772-2021 to see it in context.
Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.